Trial reportJournal of the American Heart Association2024
ELUCIDATE Trial: A Single-Center Randomized Controlled Study.
Trial report in Journal of the American Heart Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03871621. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Echocardiographic Left Ventricular Functional Changes of Uncontrolled Diabetes by the Intervention of Dapagliflozin Treatment Trial (ELUCIDATE)
Open the trial in the graphWho cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Effect of sodium-glucose cotransporter-2 inhibitors on haemoglobin and haematocrit levels in heart failure: a systematic review and meta-analysis.ESC heart failure · 2026Pooled it
- Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Left Ventricular Global Longitudinal Strain in Adults with Type 2 Diabetes Mellitus: A Systematic Review.Journal of clinical medicine · 2026Review
- Effects of SGLT2 inhibitors on cardiac structure and function in stage A and B heart failure with type 2 diabetes: a systematic review and meta-analysis.Cardiovascular diabetology. Endocrinology reports · 2026Review
- Coronary CT angiography-derived epicardial coronary volume to left ventricular mass ratio associated with myocardial ischemic events in patients with type 2 diabetes mellitus.BMC cardiovascular disorders · 2026Article
- Intraoperative pafolacianin for nodule detection during VATS metastasectomy in extremity metastatic sarcoma surgery performed concurrently.Journal of cardiothoracic surgery · 2026Article
- Shedding light on the effects of sodium-glucose cotransporter 2 inhibitors in the early stages of heart failure.World journal of cardiology · 2025Article
- MRI in Diabetic Cardiomyopathy: Ready for Prime Time?JACC. Asia · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDapagliflozin, a sodium-glucose cotransporter 2 inhibitor, is an epochal oral antidiabetic drug that improves cardiorenal outcomes. However, the effect of early dapagliflozin intervention on left ventricular (LV) remodeling in patients with type 2 diabetes free from cardiovascular disease remains unclear. METHODS AND
resultsThe ELUCIDATE trial was a prospective, open-label, randomized, active-controlled study that enrolled 76 patients with asymptomatic type 2 diabetes with LV ejection fraction ≥50%, randomized to the dapagliflozin 10 mg/day add-on or standard-of-care group. Speckle-tracking echocardiography-based measurements of the cardiac global longitudinal strain were performed at baseline and 24 weeks after treatment initiation. Patients who received dapagliflozin had a greater reduction in LV dimension (1.68 mm [95% CI, 0.53-2.84];
conclusionsDapagliflozin add-on therapy could lead to more favorable cardiac remodeling accompanied by enhanced cardiac mechanical function among patients with asymptomatic type 2 diabetes. Our findings provide evidence of the efficacy of dapagliflozin use for the primary prevention of diabetic cardiomyopathy. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03871621.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.